Viropro to File a Consent Resolution

IRVINE, Calif.--(BUSINESS WIRE)-- VIROPRO (PK: VPRO) announces a consent resolution will be filed along with the coming audited financial results; therefore it will not be holding the stockholders meeting called for July 28.

About Viropro, Inc.:

Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., and Biologics Process Development, Inc. and specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs. (www.viropro.com)

Viropro Inc. Safe Harbor Statement

Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.



CONTACT:

Viropro
Serge Beausoleil, 514-779-7336
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Genetics  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.